
    
      Study 13-HMedIdeS-02 (EudraCT no. 2013-005417-13) is a single centre, single arm, dose
      finding, Phase II study in sensitized CKD patients assessing safety, tolerability,
      pharmacokinetics (PK) and efficacy of HMED-IdeS without intent to transplantation. However,
      patients are not removed from the transplant waitlist during the study. Included patients has
      a panel reactive antibody [PRA] >70% (n=7).
    
  